F-star Therapeutics (FSTX)

Executive Summary

F-star Therapeutics is a UK-based biotechnology company pioneering the development of next-generation bispecific antibodies for cancer immunotherapy. Leveraging its proprietary Fcab and mAb2 platforms, the company engineers tetravalent, bispecific antibodies that simultaneously engage two distinct targets on immune cells and tumor cells, enhancing anti-tumor activity while minimizing off-target effects. F-star's lead program, FS118, targets PD-L1 and LAG-3, aiming to overcome resistance to checkpoint inhibitors. Additional programs in early development target other immune checkpoints and tumor-associated antigens, with the goal of creating more potent and durable responses in patients with solid tumors. Currently in the clinical stage, F-star has reported encouraging preliminary data from Phase 1 studies of FS118, demonstrating a manageable safety profile and early signs of efficacy. The company is advancing its pipeline toward pivotal trials and actively pursuing strategic partnerships to expand its platform's potential. With a strong intellectual property position and a differentiated approach to bispecific antibody design, F-star is well-positioned to address significant unmet needs in oncology. Upcoming catalysts include key data readouts, trial initiations, and potential business development activities that could drive near-term value.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 data readout for FS118 (PD-L1 x LAG-3 bispecific antibody)70% success
• Q1 2027Initiation of Phase 2 study for FS118 in a new tumor indication80% success
• 2026Partnership or licensing deal for Fcab or mAb2 platform40% success